Therapeutic chromone compounds

Details Therapeutic chromone compounds Therapeutic chromone compounds

2006-04-11

2006-04-11

Berch, Mark L. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S233500, C514S241000, C514S252110, C514S253050, C514S253060, C514S253110, C514S253100, C514S254030, C514S254050, C514S254060, C514S254090, C514S254010, C514S254110, C514S218000, C544S062000, C544S121000, C544S180000, C544S357000, C544S360000, C544S362000, C544S363000, C544S368000, C544S369000, C544S370000, C544S371000, C544S372000, C544S373000, C544S376000, C540S575000

Reexamination Certificate

active

07026314

ABSTRACT:
Provided herein is a compound of the formula (I) wherein said compound is useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating, disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1Bantagonists. Also provided herein are processes for making compounds of Formula (I) and intermediate compounds.

REFERENCES:
patent: 3862143 (1975-01-01), Klutchko et al.
patent: 3937837 (1976-02-01), Klutchko et al.
patent: 4189498 (1980-02-01), Kabbe et al.
patent: 4307020 (1981-12-01), Kabbe et al.
patent: 5112856 (1992-05-01), Gaginella et al.
patent: 5171865 (1992-12-01), Kurono et al.
patent: 5403842 (1995-04-01), Leonardi et al.
patent: 5605896 (1997-02-01), Leonardi et al.
patent: 6153625 (2000-11-01), Peglion et al.
patent: 6552054 (2003-04-01), Yasuma et al.
patent: 2331138 (1974-01-01), None
patent: 0000377 (1979-01-01), None
patent: 0017578 (1980-10-01), None
patent: 0104018 (1984-03-01), None
patent: 0546389 (1993-06-01), None
patent: 2177084 (1987-01-01), None
patent: 2001-261657 (2001-09-01), None
patent: WO 9109853 (1991-07-01), None
patent: WO 9429293 (1994-06-01), None
patent: WO 9734883 (1997-09-01), None
patent: WO 9827058 (1998-06-01), None
patent: WO 9827080 (1998-06-01), None
patent: WO 9914207 (1999-03-01), None
patent: WO 9914212 (1999-03-01), None
patent: WO 9914213 (1999-03-01), None
patent: WO 0012623 (2000-03-01), None
patent: WO 0116127 (2001-03-01), None
Thomas A. Godwin (Gastrointestinal Diseases, <http://edcenter.med.cornell.edu/CUMC—PathNotes/Gastrointestinal/Gastrointestinal.html>, 51 pages).
PCT Written Opinion PCT/SE02/00070.
PCT Written Opinion PCT/SE02/00069.
PCT Written Opinion PCT/SE02/00068.
International Search Report for International Application No. PCT/SE02/00070.
International Search Report for International Application No. PCT/SE02/00069.
International Search Report for International Application No. PCT/SE02/00068.
Barnes, et al., “A review of central 5-HT receptors and their funciton”, Neuropharmacology 38, 1083-1152, (1999).
Berg et al., “(R)-(+)-2-[[[3-(Morpholinomethyl)-2H-chromen-8-yl]oxy]methyl]morpholine Methanesulfonate: A new selective rat 5-Hydroxytryptamine 1B receptor antagonist”, J. Med. Chem. vol. 41, 1934-1942 (1998).
Clitherow, et al., “Evolution of a novel series of . . . antogonists”, Jouranl of Medicinal Chemistry, vol. 34 No 15 2253-2257.
Cryan, et al., “5-HT1A and Beyond: The Role of Serotonin and its Receptors in Depresion and the Antidepressant Response”, Hum. Psychopharmacol. Clin. Exp., 15, 113-115 (2000).
Gaster, et al., “The Selective 5-HT1b Receptor Inverse Agonist . . . (SB-224289) Potently Blocks Terminal 5-HT Autoreceptor Function Both in Vitro and in Vivo” J. Med. Chem., 41, 1218-1235 (1998).
Halazy, et al., “5-HT1B/1D antagonists and depression”, Exp. Opin. Ther. Patents, 7(4) 339352 (1997).
Massot, et al., “5-HT1B Receptors: A Novel Target for Lithium”, Neuropsychopharmacology vol. 21, No. 4, 530-541.
Raposo, et al., “The effect of chromenone receptors on the selectivity of the reaction between pyrrolidine and 5-Hydroxymethyl-2-(5H)-furanone”, Chemistry Letters, 173-174 (1997).
Russel, et al., “3-[3-(piperidin-1-yl)propyl]indoles as Highly Selective h5-HT1D Receptor Agonist”, J. Med. Chem., 42, 4981-5001, (1999).
Frank Kerrigan et al, “Synthesis of Arylpiperazines via Palladium-Catalysed Aromatic Amination Reactions of Bromoarenes with N-tert-butoxycarbonylpiperazine,” Tetrahedron Letters, vol. 39, 1998, p. 2219-2222.
International Search Report.

Affiliated with

Also associated with

Rating

Therapeutic chromone compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic chromone compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic chromone compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3573210